Committee for Orphan Medicinal Products (COMP)
Draft agenda for the meeting on 14-15 March 2017

Chair: Bruno Sepodes – Vice-Chair: Lesley Greene
14 March 2017, 08:30-19:30, room 2F
15 March 2017, 08:30-19:30, room 2F

Health and safety information
In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
### Table of contents

1. **Introduction**

   1.1. Welcome and declarations of interest of members and experts ................. 5

   1.2. Adoption of agenda ....................................................................................... 5

   1.3. Adoption of the minutes ................................................................................ 5

2. **Applications for orphan medicinal product designation**

   2.1. For opinion ..................................................................................................... 5

      2.1.1. - EMA/OD/293/16 .................................................................................... 5

      2.1.2. - EMA/OD/308/16 .................................................................................... 5

      2.1.3. - EMA/OD/253/16 .................................................................................... 6

      2.1.4. - EMA/OD/314/16 .................................................................................... 6

      2.1.5. - EMA/OD/299/16 .................................................................................... 7

      2.1.6. - EMA/OD/286/16 .................................................................................... 7

      2.1.7. - EMA/OD/287/16 .................................................................................... 7

      2.1.8. - EMA/OD/313/16 .................................................................................... 7

      2.1.9. - EMA/OD/315/16 .................................................................................... 8

      2.1.10. - EMA/OD/301/16 .................................................................................. 9

      2.1.11. - EMA/OD/294/16 .................................................................................. 10

      2.1.12. - EMA/OD/302/16 .................................................................................. 10

      2.1.13. - EMA/OD/309/16 .................................................................................. 10

      2.1.14. - EMA/OD/270/16 .................................................................................. 10

   2.2. For discussion / preparation for an opinion ................................................... 11

      2.2.1. - EMA/OD/319/16 ................................................................................... 11

      2.2.2. - EMA/OD/323/16 ................................................................................... 11

      2.2.3. - EMA/OD/329/16 ................................................................................... 11

      2.2.4. - EMA/OD/260/16 ................................................................................... 11

      2.2.5. - EMA/OD/326/16 ................................................................................... 13

      2.2.6. - EMA/OD/317/16 ................................................................................... 13

      2.2.7. - EMA/OD/316/16 ................................................................................... 13

   2.3. Revision of the COMP opinions .................................................................... 13

   2.4. Amendment of existing orphan designations ................................................. 14

   2.5. Appeal ............................................................................................................. 14

      2.5.1. 20% I.V. fat emulsion consisting of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection - EMA/OD/062/16 ...................... 14

   2.6. Nominations .................................................................................................... 14

      2.6.1. New applications for orphan medicinal product designation - Appointment of COMP coordinators ................................................. 14

   2.7. Evaluation on-going ......................................................................................... 14
3. Requests for protocol assistance with significant benefit question

<table>
<thead>
<tr>
<th>3.1.</th>
<th>Ongoing procedures</th>
<th>14</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1.1</td>
<td>-</td>
<td>14</td>
</tr>
<tr>
<td>3.1.2</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>3.1.3</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>3.1.4</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>3.1.5</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>3.1.6</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>3.1.7</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>3.2.</td>
<td>Finalised letters</td>
<td>15</td>
</tr>
<tr>
<td>3.2.1</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>3.3.</td>
<td>New requests</td>
<td>15</td>
</tr>
</tbody>
</table>

4. Review of orphan designation for orphan medicinal products for marketing authorisation

<table>
<thead>
<tr>
<th>4.1.</th>
<th>Orphan designated products for which CHMP opinions have been adopted</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2.</td>
<td>Orphan designated products for discussion prior to adoption of CHMP opinion</td>
<td>15</td>
</tr>
<tr>
<td>4.2.1</td>
<td>- pentosan polysulfate sodium – EMA/OD/179/14, EU/3/14/1411, EMEA/H/C/004246</td>
<td>16</td>
</tr>
<tr>
<td>4.2.2</td>
<td>- dinutuximab beta - EMA/OD/112/12, EU/3/12/1062, EMEA/H/C/003918</td>
<td>16</td>
</tr>
<tr>
<td>4.2.3</td>
<td>- cerliponase alfa - EMA/OD/177/12, EU/3/13/1118, EMEA/H/C/004065</td>
<td>16</td>
</tr>
<tr>
<td>4.2.4</td>
<td>- nonacog beta pegol – EMEA/OD/005/09, EU/3/09/640, EMEA/H/C/004178</td>
<td>16</td>
</tr>
<tr>
<td>4.2.5</td>
<td>- nusinersen – EMEA/H/C/004312, EMA/OD/141/11, EU/3/12/976</td>
<td>16</td>
</tr>
<tr>
<td>4.3.</td>
<td>Appeal</td>
<td>16</td>
</tr>
<tr>
<td>4.4.</td>
<td>On-going procedures</td>
<td>17</td>
</tr>
<tr>
<td>4.5.</td>
<td>Public Summary of Opinions</td>
<td>17</td>
</tr>
</tbody>
</table>

5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension

<table>
<thead>
<tr>
<th>5.1.</th>
<th>After adoption of CHMP opinion</th>
<th>17</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.2.</td>
<td>Prior to adoption of CHMP opinion</td>
<td>17</td>
</tr>
<tr>
<td>5.2.1</td>
<td>Nplate - recombinant megakaryopoiesis-stimulating protein – EMEA/OD/008/05, EU/3/05/283, EMA/H/C/000942/II/0060/G</td>
<td>17</td>
</tr>
<tr>
<td>5.3.</td>
<td>Appeal</td>
<td>17</td>
</tr>
</tbody>
</table>

6. Application of Article 8(2) of the Orphan Regulation

<table>
<thead>
<tr>
<th>7.</th>
<th>Organisational, regulatory and methodological matters</th>
<th>17</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.1.</td>
<td>Mandate and organisation of the COMP</td>
<td>17</td>
</tr>
<tr>
<td>7.1.1</td>
<td>Protocol Assistance Working Group</td>
<td>17</td>
</tr>
<tr>
<td>7.1.2</td>
<td>Strategic Review &amp; Learning meetings</td>
<td>17</td>
</tr>
<tr>
<td>7.1.3</td>
<td>COMP meeting dates for 2019, 2020 and 2021</td>
<td>18</td>
</tr>
</tbody>
</table>
7.2. Coordination with EMA Scientific Committees or CMDh-v ........................................... 18
7.2.1. PDCO/COMP Working Group ............................................................................. 18
7.2.2. Recommendations on eligibility to PRIME – report from CHMP ....................... 18
7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ... 18
7.4. Cooperation within the EU regulatory network ......................................................... 18
7.4.1. European Commission ...................................................................................... 18
7.5. Cooperation with International Regulators ............................................................ 18
7.5.1. Food and Drug Administration (FDA) ...................................................................... 18
7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA) ....................... 18
7.5.3. The Therapeutic Goods Administration (TGA), Australia ..................................... 18
7.5.4. Health Canada .................................................................................................. 18
7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee ........................................................................ 19
7.7. COMP work plan .................................................................................................. 19
7.7.1. COMP Work Plan 2017 .................................................................................... 19
7.8. Planning and reporting ......................................................................................... 19
7.8.1. List of all applications submitted/expected and the COMP coordinatorship distribution of valid applications submitted in 2017 ......................................................... 19
7.8.2. Overview of orphan marketing authorisations/applications .............................. 19
8. Any other business ..................................................................................................... 19
8.1. EMA Business Pipeline activity and Horizon scanning ........................................... 19
9. Explanatory notes ..................................................................................................... 19
### 1. Introduction

#### 1.1. Welcome and declarations of interest of members and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the COMP plenary session to be held 14-15 March 2017. See March 2017 COMP minutes (to be published post April 2017 COMP meeting).

#### 1.2. Adoption of agenda


#### 1.3. Adoption of the minutes

COMP minutes for 14-16 February 2017.

### 2. Applications for orphan medicinal product designation

#### 2.1. For opinion

##### 2.1.1. - EMA/OD/293/16

Treatment of fragile X syndrome

**Action:** For adoption, Oral explanation to be held on 14 March 2017 at 09:30

Documents tabled:
Draft Summary report with response to LoQs

Notes:
There have been 7 designations for this condition: EMA/OD/144/10 R-baclofen, EMA/OD/059/12 Mavoglurant, EMA/OD/105/14 (3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one, EMA/OD/137/14 Acamprosate calcium, EMA/OD/253/14 Tidegusib, EMA/OD/055/15 Glycyl-L-2-methylpropyl-L-glutamic acid, EMA/OD/034/16 Pyridoxine and L-pyroglutamic acid

##### 2.1.2. - EMA/OD/308/16

Treatment of acromegaly

**Action:** For adoption, Oral explanation to be held on 14 March 2017 at 11:00

Documents tabled:
Draft Summary report with response to LoQs

Notes:
There have been 5 designations for this condition: EMEA/OD/010/09 Octreotide chloride (lipid depot solution), EMEA/OD/051/09 Pasireotide, EMA/OD/107/12 Cyclo(-gamma-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt, EMA/OD/042/13 Octreotide
acetate (oral use), EMA/OD/023/16 2′-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting the growth hormone receptor

Designation withdrawn: EMA/OD/108/11 Recombinant protein consisting of modified human growth hormone releasing hormone and the translocation and endopeptidase domains of botulinum toxin serotype D

2.1.3. - EMA/OD/253/16

Treatment of invasive aspergillosis

**Action:** For adoption, Oral explanation to be held on 14 March 2017 at 14:30

Documents tabled:
Draft Summary report with response to LoQs

Notes:
There have been 2 designations for this condition: EMA/OD/009/14 Isavuconazonium sulfate, EMA/OD/104/16 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoropyrimidin-2-yl) piperazin-1-yl]-phenyl}-2-oxo-acetamide

2.1.4. - EMA/OD/314/16

Treatment of ovarian cancer

**Action:** For adoption, Oral explanation to be held on 14 March 2017 at 12:00

Documents tabled:
Draft Summary report with response to LoQs

Notes:
There have been 30 designations for this condition: EMEA/OD/019/02 Oregovomab, EMEA/OD/061/06 Paclitaxel (micellar), EMEA/OD/080/03 Anti-epithelial cell adhesion molecule/anti-CD3 monoclonal antibody, EMEA/OD/044/03 Trabectedin, EMEA/OD/065/05 Imexon, EMEA/OD/063/07 Olaparib, EMEA/OD/110/07 Humanised monoclonal antibody to the folate receptor alpha, EMEA/OD/006/09 Human MHC non-restricted cytotoxic T-cell line, EMEA/OD/086/09 8-[4-[1-aminocyclobutyl]phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one mono-hydrochloride, EMA/OD/015/10 (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt, EMA/OD/021/10 Autologous dendritic cells pulsed with recombinant human-fusion protein (mucin 1 - glutathione S transferase) coupled to oxidised polymannose, EMA/OD/014/10 Pyr-His-Trp-Ser-Tyr-D-Lys(oxorubicinylglutarate)-Leu-Arg-Pro-Gly-NH2, acetate salt, EMA/OD/111/10 Veliparib, EMA/OD/054/11 20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4′-bipiperidine]-1′-carboxylate, EMA/OD/151/11 2-Allyl-1-[6-(1-hydroxy-1-methyllethyl)pyridin-2-yl]-6-[(4-methylpiperazin-1-yl)amino]-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one, EMA/OD/085/12 rucaparib, EMA/OD/099/12 Lurbinectedin, EMA/OD/147/12 Chimeric monoclonal antibody against claudin 6, EMA/OD/039/13 Fosbetabulin tromethamine, EMA/OD/122/13 Trebananib, EMA/OD/186/13 Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor, EMA/OD/059/14 Cediranib, EMA/OD/281/14 Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4, EMA/OD/157/14 2-hydroxymethyl-2-methoxyethyl-1-azabicyclo[2,2,2]octan-3-one, EMA/OD/211/14 Chimeric group B adenovirus (11p/3) with
deletions in the E3 and E4 regions, EMA/OD/223/14 N-methyl-4-((3-methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl)amino)benzamide hydrochloride, EMA/OD/304/14 Human reovirus type 3 Dearing strain, EMA/OD/314/14 (2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl]-3H-benzo[f]azepin-4-yl]-N,N-dipropylcarboxamide, EMA/OD/126/15 (S,S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a]1,5-diazocine-8-carboxamide, EMA/OD/159/16 Vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions

Designations withdrawn: EMEA/OD/061/00 Human Milk Fat Globule 1 / Yttrium (90Y) human Milk Fat Globule 1 - S p isothiocyanatobenzyl-diethylenetriaminepentaacetic acid, EMEA/OD/062/01 Epothilone B, EMEA/OD/016/03 Murine anti-idiotypic antibody against OC125 antibody against CA125 antigen, EMEA/OD/071/09 Anti-EphA2 monoclonal antibody conjugated to maleimidocaproyl monomethylauristatin phenylalanine, EMA/OD/094/11 Vincaleukoblastin-23-oic acid, O4-deacetyl-2-[(2-mercaptoethoxy)carbonyl]hydrazide, disulfide with ..., EMA/OD/002/12 1-(4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno [3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea, EMA/OD/114/12 Alisertib

2.1.5. - EMA/OD/299/16

Treatment of pulmonary arterial hypertension

**Action:** For adoption, Oral explanation to be held on 14 March 2017 at 18:00

Documents tabled:
Draft Summary report with response to LoQs

Notes:
There have been 4 designations for this condition: EMEA/OD/018/08 Beraprost sodium, EMA/OD/023/11 Macitentan, EMA/OD/111/11 Sodium nitrite, EMA/OD/179/15 Ubenimex

2.1.6. - EMA/OD/286/16

Treatment of graft rejection following solid organ transplantation

**Action:** For adoption, Oral explanation to be held on 15 March 2017 at 09:00

Documents tabled:
Draft Summary report with response to LoQs

2.1.7. - EMA/OD/287/16

Treatment of graft rejection following solid organ transplantation

**Action:** For adoption, Oral explanation to be held on 15 March 2017 at 09:00

Documents tabled:
Draft Summary report with response to LoQs

2.1.8. - EMA/OD/313/16

Treatment of Asherman's syndrome

**Action:** For adoption, Oral explanation to be held on 15 March 2017 at 10:00
Documents tabled:
Draft Summary report with response to LoQs

2.1.9. - EMA/OD/315/16

Treatment of acute myeloid leukaemia

**Action:** For adoption, Oral explanation to be held on 15 March 2017 at 11:00

Documents tabled:
Draft Summary report with response to LoQs

**Notes:**

There have been 49 designations for this condition: EMEA/OD/022/00 Gemtuzumab ozogamicin, EMEA/OD/028/04 Midostaurin, EMEA/OD/056/06 Antisense oligonucleotide 5'-d[P-Thio] (CCCTG CTCCC CCCTG GCTCC)-3' (see comments box for cenersen sodium), EMEA/OD/098/04 Tipifarnib, EMA/OD/094/04 Histamine dihydrochloride, EMA/OD/066/05 1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine, EMA/OD/100/05 zosuquidar trihydrochloride, EMA/OD/004/06 Decitabine, EMA/OD/049/07 5'-O-(trans-9'-octadecenoyl)-1-β-D-arabinofuranosyl cytosine, EMA/OD/087/07 Recombinant human histone H1.3 and recombinant human N-bis-methylhistone H1.3, EMA/OD/085/07 Azacitidine, EMA/OD/099/07 N-(2-Amino-phenyl)-4-[(4-pyrindin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide, EMA/OD/118/07 Ribonucleotide reductase R2 specific phosphorothioate oligonucleotide, EMEA/OD/015/08 Sapacitabin, EMA/OD/048/08 Daunorubicin (liposomal), EMA/OD/105/08 N-(5-tert-Butylisoxazol-3-yl)-N'-(4-[7-(2-(moropholin-4-yl)-ethoxy)methyl]-imidazo[2,1-b][1,3]benzothiazol-2-yl)phenyl)urea dihydrochloride salt, EMA/OD/028/09 Tosedostat, EMA/OD/091/09 1-Cyclopentylpropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, EMA/OD/147/09 2-methoxymethyl-2-hydroxymethyl-1-azabicyclo[2,2,2]octan-3-one, EMA/OD/044/10 Allogeneic T cells encoding an exogenous TK gene, EMA/OD/094/10 N-(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl) amino]isonicotinamide hydrochloride, EMA/OD/161/10 Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2, EMA/OD/101/11 Allogeneic human dendritic cells derived from a CD34+ progenitor cell line, EMA/OD/070/11 Liposomal combination of cytarabine and daunorubicin, EMA/OD/158/11 Vosaroxin, EMA/OD/167/12 L-asparaginase encapsulated in erythrocytes, EMA/OD/064/13 trans-N1-((1R,2S)-2-phencylcyclopropyl)cyclohexane-1,4-diamine bis-hydrochloride, EMA/OD/141/13 (2R,3R,4S,5R)-2-((6-amino-9H-purin-9-yl)-5-(((1r,3S)-3-(2-(5-(tert-butyl)-1Hbenzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol, EMA/OD/181/13 Volasertib, EMA/OD/100/14 4-\{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino\}-3-methoxy-benzoic acid, EMA/OD/061/14 (Z)-3-((3,3,5-bis(trifluoromethyl)phenyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-pyrazin-2-yl)acryloylhydrazide, EMA/OD/103/14 Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment, EMA/OD/175/14 Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells, EMA/OD/240/14 Alvocidib, EMA/OD/188/14 Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells / allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells, EMA/OD/258/14 Ulocuplumab, EMA/OD/045/15 inecalcitol, EMA/OD/037/15 2-(((3-((4-((3aminopropyl)amino)butyl) amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)acetamide,


2.1.10.  - EMA/OD/301/16

Treatment of narcolepsy

**Action:** For adoption, Oral explanation to be held on 15 March 2017 at 12:00

Documents tabled:
- Draft Summary report with response to LoQs

Notes:
- There have been 3 designations for this condition:  EMEA/OD/087/06 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride, EMA/OD/254/14 Mazindol, EMA/OD/002/15 Mazindol
- Designation withdrawn:  EMEA/OD/051/02 Sodium oxybate
2.1.11. - EMA/OD/294/16

Treatment of calciphylaxis

**Action:** For adoption, Oral explanation to be held on 15 March 2017 at 14:30

Documents tabled:
Draft Summary report with response to LoQs

Notes:
There have been 3 designations for this condition: EMA/OD/116/10 Sodium thiosulfate, EMA/OD/149/11 Sodium thiosulfate, EMA/OD/043/12 Hex sodium phytate

2.1.12. - EMA/OD/302/16

Treatment of epidermolysis bullosa due to mutations in the *COL7A1* gene

**Action:** For information

Documents tabled:
Withdrawal request of 23 February 2017

2.1.13. - EMA/OD/309/16

Treatment of neonatal encephalopathy

**Action:** For adoption, Oral explanation to be held on 15 March 2017 at 17:00

Documents tabled:
Draft Summary report with response to LoQs

Notes:
There has been 1 designation for this condition: EMA/OD/141/16 Autologous mononuclear cells derived from human cord blood

2.1.14. - EMA/OD/270/16

Treatment of multiple myeloma

**Action:** For adoption, Oral explanation to be held on 15 March 2017 at 15:30

Documents tabled:
Draft Summary report with response to LoQs

Notes:
There have been 14 designations for this condition: EMEA/OD/040/01 Thalidomide, EMEA/OD/063/03 3-((4'-aminoisoindoline-1'-one)-1-piperidine-2,6-dione, EMEA/OD/044/04 Aplidine, EMEA/OD/066/04 Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors, EMEA/OD/012/05 N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole, EMEA/OD/120/07 Carfilzomib, EMEA/OD/068/08 N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthylidithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 monoclonal antibody, EMEA/OD/076/08 Human anti-intercellular adhesion molecule-1 monoclonal antibody, EMEA/OD/053/08 Milatuzumab, EMEA/OD/053/09 Pomalidomide, EMA/OD/017/11 Acadesine, EMA/OD/048/11 2,2'-(2-[(1R)-1-((2,5-dichlorobenzoyl)amino)acetyl]amino)-3-methylbutyl]-5-oxo-1,3,2-
dioxaborolane-4,4-diyl)diacetic acid, EMA/OD/113/12 Panobinostat, EMA/OD/121/16 Venetoclax

Designations withdrawn: EMEA/OD/048/00 Arsenic trioxide, EMEA/OD/003/01 Humanised anti-HM1.24 monoclonal antibody, EMEA/OD/018/00 Thalidomide, EMEA/OD/026/01 Deoxyribose phosphorothioate (5'-tct-ccc-agc-gtg-cgc-cat-3'), EMEA/OD/019/01 Thalidomide, EMEA/OD/070/04 17-allylamino-17-demethoxygeldanamycin, EMEA/OD/093/05 Human monoclonal antibody against HLA-DR, EMEA/OD/003/09 Chimeric-anti-interleukin-6 monoclonal antibody, EMEA/OD/133/09 Dexamethasone (40 mg tablet), EMEA/OD/130/09 Perifosine, EMA/OD/115/10 Maytansinoid-conjugated humanised monoclonal antibody against CD56, EMA/OD/137/10 Vorinostat, EMA/OD/137/11 Chimeric monoclonal antibody against kappa myeloma antigen, EMA/OD/061/12 Elotuzumab

2.2. **For discussion / preparation for an opinion**

2.2.1. - EMA/OD/319/16

Treatment of acute myeloid leukaemia

**Action:** For adoption

Documents tabled:
Draft Summary report

Notes:
There have been 49 designations for this condition: Please see 2.1.9.

2.2.2. - EMA/OD/323/16

Treatment of Herpes simplex encephalitis

**Action:** For adoption

Documents tabled:
Draft Summary report

2.2.3. - EMA/OD/329/16

Prevention of mercury toxicity

**Action:** For adoption

Documents tabled:
Draft Summary report

2.2.4. - EMA/OD/260/16

Treatment of glioma

**Action:** For adoption

Documents tabled:
Draft Summary report

Notes:
There have been 43 designations for this condition: EMEA/OD/026/03 Herpes simplex virus lacking infected cell protein 34.5, EMEA/OD/055/03 Gimatecan, EMEA/OD/050/04 Anti epidermal growth factor receptor antibody h-R3, EMEA/OD/030/05 Oligonucleotide phosphorothioate (TAAACGTTATAACGTTAGACGTCAT), sodium salt, EMEA/OD/068/05 Enzastaurin hydrochloride, EMEA/OD/110/05 4-[131I] iodo-L-phenylalanine, EMEA/OD/081/06 Autologous dendritic cells pulsed with autologous tumour cell lysate, EMEA/OD/050/07 Doxorubicin hydrochloride (drug eluting beads), EMEA/OD/051/07 Irinotecan hydrochloride (drug eluting beads), EMEA/OD/038/07 Iodine (131I) Chlorotoxin, EMEA/OD/004/08 Recombinant fusion protein of circulary-permuted IL-4 and pseudomonas exotoxin A, [IL-4(38-37)-PE38KDEL], EMEA/OD/023/08 Topotecan hydrochloride (liposomal), EMEA/OD/034/08 Gadodiamide (liposomal), EMEA/OD/104/08 Autologous tumour-derived gp96 heat shock protein-peptide complex, EMEA/OD/098/09 Recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule, EMA/OD/086/10 7-beta-hydroxycholesteryl-3-beta-oleate, EMA/OD/092/12 IL-12-secreting dendritic cells, loaded with autologous tumour lysate, EMA/OD/077/11 L-cysteine, L-leucyl-L-alpha-glutamy-L-alpha-glutamy-L-L-lysyl-L-L-lysylglcyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-[1-[[4-carboxycyclohexyl]methyl]-2,5-dioxo-3-pyrolidinyl]-complex with keyhole limninator_Applica, EMA/OD/050/11 2-hydroxyoleic acid, EMA/OD/157/11 Adenovirus-associated vector containing human Fas-c gene, EMA/OD/019/12 Doxorubicin (administered after synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine), EMA/OD/170/12 4-[2-[(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate, EMA/OD/148/12 1,2,5,6-Dianhydroglactitol, EMA/OD/136/12 Synthetic double-stranded siRNA oligonucleotide directed against Claudin-5 complexed with polyethyleneimine (prior to administration of doxorubicin), EMA/OD/086/13 Autologous ex vivo expanded leukocytes treated with 5-aza-2'-deoxycytidine, EMA/OD/001/14 Autologous dendritic cells pulsed with RNA from glioma stem cells, EMA/OD/107/13 Allogeneic and autologous haptenised and irradiated cells and cell lysates derived from glioma, EMA/OD/174/13 Autologous dendritic cells pulsed with tumour antigen-derived synthetic peptides (MAGE-1, HER-2, AIM-2, TRP-2, gp-100, and interleukin-13 receptor alpha), EMA/OD/111/14 Recombinant human bone morphogenetic protein 4, EMA/OD/003/14 Paclitaxel-succinate- Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe, EMA/OD/065/14 Humanised recombinant monoclonal antibody against epidermal growth factor receptor conjugated to maleimidocaproyl monomethylauristatin F, EMA/OD/132/14 Olaptosed pegol, EMA/OD/200/14 5,5'-(4-(trifluromethyl) benzylazanediyl) bis(methylene)diquinolin-8-ol, EMA/OD/159/14 5,5'-((4-trifluromethyl) benzylazanediyl) bis(methylene)diqunolin-8-ol, EMA/OD/159/14 Chloroquine, EMA/OD/086/20 5,5'-((4-trifluromethyl) benzylazanediyl) bis(methylene)diqunolin-8-ol, EMA/OD/076/14 Adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain, EMA/OD/251/14 Recombinant human glutamate oxaloacetate transaminase 1, EMA/OD/206/15 N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine, EMA/OD/009/16 Efflornithine, EMA/OD/222/15 Delta-9-tetrahydrocannabinol and cannabidiol from extracts of the Cannabis sativa L. plant, EMA/OD/076/16 Zoledronic acid, EMA/OD/085/16 Temozolomide, EMA/OD/215/16 5-aminolevulinic acid

Designations withdrawn: EMEA/OD/004/02 Pseudomonas exotoxin (domains II/III)-Interleukin 13 chimeric protein, EMEA/OD/074/01 Human transferrin conjugated to mutant diptheria toxin, EMEA/OD/067/01 Carmustine (solution for intratumoral injection), EMEA/OD/050/06 Iodine (131I) anti-tenascin monoclonal antibody 81C6, EMEA/OD/037/02 Iodine (131I) anti-nucleohistone H1 chimeric biotinylated monoclonal antibody,
2.2.5. - EMA/OD/326/16

Treatment of ornithine transcarbamylase deficiency

**Action:** For adoption

Documents tabled:
Draft Summary report

**Notes:**
There have been 4 designations for this condition: EMEA/OD/101/07 Heterologous human adult liver derived stem cells, EMA/OD/026/11 Heterologous human adult liver-derived stem cells, EMA/OD/227/15 Adeno-associated viral vector serotype 8 encoding human ornithine transcarbamylase, EMA/OD/053/16 Sodium benzoate

Designation withdrawn: EMA/OD/097/11 Sodium phenylbutyrate Human heterologous liver cells (for infusion)

2.2.6. - EMA/OD/317/16

Treatment of thymidine kinase 2 deficiency

**Action:** For adoption

Documents tabled:
Draft Summary report

2.2.7. - EMA/OD/316/16

Treatment of Niemann-Pick disease, type C

**Action:** For adoption

Documents tabled:
Draft Summary report

**Notes:**
There have been 5 designations for this condition: EMEA/OD/090/05 miglustat, EMA/OD/033/11 Hydroxy-propyl-beta-cyclodextrin, EMA/OD/160/12 Recombinant human heat shock protein 70, EMA/OD/191/12 2-hydroxypropyl-beta-cyclodextrin, EMA/OD/158/14 Arimoclomol citrate

2.3. **Revision of the COMP opinions**

None
2.4. Amendment of existing orphan designations

None

2.5. Appeal

2.5.1. 20% I.V. fat emulsion consisting of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection - EMA/OD/062/16

Alan Boyd Consultants Ltd; Treatment of poisoning by local anesthetics

Action: For adoption, Oral explanation to be held on 14 March 2017 at time 15:30

Documents tabled:
Revised draft Summary report
Sponsor’s grounds for appeal

Notes:
Appeal of the negative COMP opinion adopted in November 2016.

2.6. Nominations

2.6.1. New applications for orphan medicinal product designation - Appointment of COMP coordinators

Action: For adoption

Document tabled:
OMPD applications - appointment of coord. at the 14-15 March 2017 COMP meeting

2.7. Evaluation on-going

Twenty one applications for orphan designation will not be discussed as evaluation is on-going.

Action: For information

Notes:
Cross reference to other agenda point. See 7.8.1. Table 6. Evaluation Ongoing.

3. Requests for protocol assistance with significant benefit question

3.1. Ongoing procedures

3.1.1. -

Treatment of Gaucher disease

Action: For adoption
3.1.2. -

Treatment of narcolepsy

**Action**: For adoption

3.1.3. -

Treatment of Langerhans cell histiocytosis

**Action**: For adoption

3.1.4. -

Treatment of Wolfram syndrome

**Action**: For information

3.1.5. -

Treatment of Wolfram syndrome

**Action**: For information

3.1.6. -

Treatment of paroxysmal nocturnal haemoglobinuria

**Action**: For adoption

3.1.7. -

Treatment of beta-thalassemia intermedia and major

**Action**: For discussion

3.2. **Finalised letters**

3.2.1. -

Treatment of amyotrophic lateral sclerosis

**Action**: For information

3.3. **New requests**

None

4. **Review of orphan designation for orphan medicinal products for marketing authorisation**

4.1. **Orphan designated products for which CHMP opinions have been adopted**
4.2. Orphan designated products for discussion prior to adoption of CHMP opinion

4.2.1. - pentosan polysulfate sodium – EMA/OD/179/14, EU/3/14/1411, EMEA/H/C/004246

Bene-Arzneimittel GmbH; Treatment of interstitial cystitis

Action: For discussion, Oral explanation to be held on 14 March 2017 at 17:00

Documents tabled:
Draft report on review of OMPD
CHMP assessment report

4.2.2. - dinutuximab beta - EMA/OD/112/12, EU/3/12/1062, EMEA/H/C/003918

APEIRON Biologics AG; Treatment of neuroblastoma

Action: For discussion

Document(s) tabled:
Draft report on review of OMPD

4.2.3. - cerliponase alfa - EMA/OD/177/12, EU/3/13/1118, EMEA/H/C/004065

BioMarin International Limited; Treatment of neuronal ceroid lipofuscinosis type 2

Action: For discussion

Documents tabled:
Draft report on review of OMPD

4.2.4. - nonacog beta pegol – EMEA/OD/005/09, EU/3/09/640, EMEA/H/C/004178

Novo Nordisk A/S; Treatment of haemophilia B

Action: For discussion

Documents tabled:
Draft report on review of OMPD

4.2.5. - nusinersen – EMEA/H/C/004312, EMA/OD/141/11, EU/3/12/976

Biogen Idec Ltd; Treatment of 5q spinal muscular atrophy

Action: For discussion

Document(s) tabled:
Draft report on review of OMPD

4.3. Appeal

None
### 4.4. On-going procedures

**Action:** For information

### 4.5. Public Summary of Opinions

**Action:** For information

### 5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension

#### 5.1. After adoption of CHMP opinion

None

#### 5.2. Prior to adoption of CHMP opinion

##### 5.2.1. Nplate - recombinant megakaryopoiesis-stimulating protein – EMEA/OD/008/05, EU/3/05/283, EMA/H/C/000942/II/0060/G

Amgen Europe BV - The Netherlands; Treatment of idiopathic thrombocytopenic purpura

**Action:** For discussion

Document(s) tabled:
Draft report on review of OMPD

#### 5.3. Appeal

None

### 6. Application of Article 8(2) of the Orphan Regulation

None

### 7. Organisational, regulatory and methodological matters

#### 7.1. Mandate and organisation of the COMP

##### 7.1.1. Protocol Assistance Working Group

Proposed meeting time on 14 March 2017 at 13:00

Document(s) tabled:
Pending

##### 7.1.2. Strategic Review & Learning meetings

None
7.1.3. **COMP meeting dates for 2019, 2020 and 2021**

**Action**: For adoption  
Document(s) tabled:  
COMP meetings dates for 2019-2021

7.2. **Coordination with EMA Scientific Committees or CMDh-v**

7.2.1. **PDCO/COMP Working Group**

Proposed meeting time on 15 March 2017 at 13:00

7.2.2. **Recommendations on eligibility to PRIME – report from CHMP**

**Action**: For information  
Document(s) tabled:  
PRIME eligibility requests - final list of outcomes for February 2017 adoption

7.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

None

7.4. **Cooperation within the EU regulatory network**

7.4.1. **European Commission**

None

7.5. **Cooperation with International Regulators**

7.5.1. **Food and Drug Administration (FDA)**

**Action**: For information  
Document tabled:  
Draft Agenda February 21, 2017

7.5.2. **Japanese Pharmaceuticals and Medical Devices Agency (PMDA)**

None

7.5.3. **The Therapeutic Goods Administration (TGA), Australia**

None

7.5.4. **Health Canada**

None
7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

None

7.7. COMP work plan

7.7.1. COMP Work Plan 2017

**Action**: For information

Document(s) tabled:
COMP Work Plan 2017

7.8. Planning and reporting

7.8.1. List of all applications submitted/expected and the COMP coordinatorship distribution of valid applications submitted in 2017

**Action**: For information

7.8.2. Overview of orphan marketing authorisations/applications

**Action**: For information

8. Any other business

8.1. EMA Business Pipeline activity and Horizon scanning

**Action**: For information

Document tabled:
Upcoming Q1/2017 Update of the Business Pipeline report for the human scientific committees

9. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the COMP agenda and should be read in conjunction with the agenda or the minutes.

**Abbreviations / Acronyms**

CHMP: Committee for Medicinal Product for Human Use
COMP: Committee for Orphan Medicinal Products
EC: European Commission
OD: Orphan Designation
PA: Protocol Assistance
PDCO: Paediatric Committee
PRAC: Pharmacovigilance and Risk Assessment Committee
SA: Scientific Advice
SAWP: Scientific Advice Working Party
**Orphan Designation** *(section 2 Applications for orphan medicinal product designation)*

The orphan designation is the appellation given to certain medicinal products under development that are intended to diagnose, prevent or treat rare conditions when they meet a pre-defined set of criteria foreseen in the legislation. Medicinal products which get the orphan status benefit from several incentives (fee reductions for regulatory procedures including protocol assistance), national incentives for research and development, 10-year market exclusivity) aiming at stimulating the development and availability of treatments for patients suffering from rare diseases.

Orphan Designations are granted by Decisions of the European Commission based on opinions from the COMP. Orphan designated medicinal products are entered in the Community Register of Orphan Medicinal Products.

**Protocol Assistance** *(section 3 Requests for protocol assistance with significant benefit question)*

The protocol assistance is the help provided by the Agency to the sponsor of an orphan medicinal product, on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product in view of the submission of an application for marketing authorisation.

**Sponsor**

Any legal or physical person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product.

**Maintenance of Orphan Designation** *(section 4 Review of orphan designation for orphan medicinal products for marketing authorisation)*

At the time of marketing authorisation, the COMP will check if all criteria for orphan designation are still met. The designated orphan medicinal product should be removed from the Community Register of Orphan Medicinal Products if it is established that the criteria laid down in the legislation are no longer met.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)